Alzheimer’s Research & Therapy is now accepting research submissions for consideration in a special series on traumatic brain injury, planned for publication in spring 2013.

Submit your paper to this series and receive a 50% article processing charge discount – simply quote ‘alzrt-TBI-50’ at submission.

Chronic Traumatic Encephalopathy (CTE) is a progressive degenerative disease of the brain found in people with a history of repetitive brain trauma. This condition has emerged as a significant public health problem, particularly among those in the military or athletes involved in contact sports such as boxing and football.

Despite the growth in media attention and cultural awareness of this condition, the science of CTE is still in its infancy.

Initially described as “Punch Drunk” in 1928 by Martland in the Journal of the American Medical Association, and later as Dementia Pugilistica and then as CTE in 1948, it has only been in the past 3-4 years that scientists and clinicians have understood that this condition can affect individuals in our society other than boxers. It is believed that CTE is caused, in part, by exposure to repetitive brain trauma years or decades prior to the initial symptom presentation. However, additional risk factors and the specific neuropathogenetic process are unknown.

The publication of these articles will be co-ordinated with a series of commissioned reviews and opinions, addressing a range of topics pertinent to CTE. Guest edited by Prof Robert Stern (Boston) and written by leaders in the field including Charles Bernick (Cleveland Clinic), Alexander Lin (Brigham and Women’s Hospital), Martha Shenton (Harvard) and Everett Lehman (CDC), these articles will review the neuropathology, neuropathogenesis, and clinical aspects of this tauopathy, including clinical presentation, neuroimaging, and diagnostic features.

The deadline for submissions is 31st March 2013. Please submit online and indicate in your covering letter that you would like the article to be considered for the traumatic brain injury series.

Benefits of publishing in Alzheimer’s Research & Therapy include:

• Alzheimer’s Research & Therapy being recently ranked by Scopus as 3rd in the neurology category, 6th in the cognitive neuroscience category and one of the top 50 open access journals in the world
• Open access research means freely available online, immediately, to a global audience
• International and rapid peer-review (first decision provided within 6 weeks)
• Prestigious Editorial Board
• Immediate publication on acceptance
• Inclusion in PubMed and PubMed Central
• No color figure charges or space limits

If you would like to enquire about the suitability of a study for consideration, please email editorial@alzres.com.

For further information about the journal, please visit the website, or contact us for enquires about the special series.